BioSpace News Archive

Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced program updates and upcoming 2024 milestones.

Sensorion announces that the research partnership framework agreement signed in 2019 with the Institut Pasteur granting Sensorion an option for exclusive licenses to develop and market gene therapy drug candidates from collaborative projects to address unmet medical needs in the hearing field has been extended for a period of five years.

selectION, Inc. announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference.

SanReno Therapeutics, a clinical-stage company specializing in the discovery, development, and commercialization of innovative therapies for kidney diseases, announces its acquisition by Novartis, a global medicines company.

Omniose, a preclinical biotechnology company, today announced an exclusive collaboration agreement with AstraZeneca to research potential vaccines for bacterial pathogens in AstraZeneca’s early Vaccines & Immune Therapies pipeline.

Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, highlighted its 2023 accomplishments and upcoming milestones.

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has received CE (Conformité Européenne) Mark for its Micra™ AV2 and Micra™ VR2, the next generation of its industry-leading miniature, leadless pacemakers.

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”) today announced filing of a new patent application relating to composition and methods for combining GLP-1ra and foralumab, a fully human anti-CD3 antibody, to achieve further reductions in systemic and vascular inflammation associated with Type 2 Diabetes (T2D) and also in a separate population of patients with non T2D obesity.

Pharvaris, a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema attacks, provided business updates and outlined its strategic priorities for 2024.

Verrica Pharmaceuticals Inc. today announced that the last patient has been dosed in Part 2 of the Company’s Phase 2 trial of VP-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma.